I'm a provider
You will be redirected to myBlue. Would you like to continue?
Please wait while you are redirected.
DESCRIPTIONFragile X syndrome is the most common inherited form of mental disability and known genetic cause of autism. The diagnosis includes use of a genetic test that determines the number of CGG repeats in the fragile X gene.
Fragile X Syndrome
Fragile X syndrome (FXS) is the most common cause of heritable mental retardation, characterized by moderate mental retardation in males and mild mental retardation in females. FXS affects approximately one in 4,000 males and one in 8,000 females. In addition to the intellectual impairment, patients present with typical facial characteristics such as an elongated face with a prominent forehead, protruding jaw, and large ears.
Connective tissue anomalies include hyperextensible finger and thumb joints, hand calluses, velvet-like skin, flat feet and mitral valve prolapse. The characteristic appearance of adult males includes macroorchidism. Patients may show behavioral problems including autism spectrum disorders, sleeping problems, social anxiety, poor eye contact, mood disorders and hand-flapping or biting. Another prominent feature of the disorder is neuronal hyperexcitability, manifested by hyperactivity, increased sensitivity to sensory stimuli and a high incidence of epileptic seizures.
Approximately 1-3% of children ascertained on the basis of autism diagnosis are shown to have fragile X syndrome, with expansion of the CGG trinucleotide repeat in the FMR1 gene to full mutation size of 200 or more repeats. A considerable number of children being evaluated for autism have been found to have FMR1 premutations (55-200 CGG repeats). In one author’s experience, 2% of persons ascertained through a dedicated autism clinic had either an FMR1 full mutation or premutation.
Treatment of Fragile X Syndrome
Current approaches to therapy are supportive and symptom-based. Psychopharmacologic intervention to modify behavioral problems in a child with fragile X syndrome may represent an important adjunctive therapy when combined with other supportive strategies including speech therapy, occupational therapy, special educational services, and behavioral interventions. Medication management may be indicated to modify attention deficits, problems with impulse control, and hyperactivity. Anxiety-related symptoms, including obsessive compulsive tendencies with perseverative behaviors, also may be present and require medical intervention. Emotional lability and episodes of aggression and self-injury may be a danger to the child and others around him or her; therefore, the use of medication(s) to modify these symptoms also may significantly improve an affected child’s ability to participate more successfully in activities in home and school settings.
Genetics of Fragile X Syndrome
FXS is associated with the expansion of the CGG trinucleotide repeat in the fragile X mental retardation 1 (FMR1) gene on the X chromosome. Diagnosis of FXS may include using a genetic test that determines the number of CGG repeats in the fragile X gene. The patient is classified as normal, intermediate (or “gray zone”), premutation or full mutation based on the number of CGG repeats.
Patients with a full mutation are associated with FXS, which is caused by expansion of the FMR1 gene CGG triplet repeat above 200 units in the 50 untranslated region of FMR1, leading to a hypermethylation of the promoter region followed by transcriptional inactivation of the gene. The FXS is caused by a loss of the fragile X mental retardation protein (FMRP).
Those with a premutation are carriers and may have a FMR1-related disorder: fragile X-associated tremor/ ataxia syndrome (FXTAS), which is a late onset, progressive development of intention tremor and ataxia often accompanied by progressive cognitive and behavioral difficulties including memory loss, anxiety, reclusive behavior, deficits of executive function and dementia or premature ovarian insufficiency (POI).
Premutation alleles in females are unstable and may expand to full mutations in offspring. Premutations of less than 59 repeats have not been reported to expand to a full mutation in a single generation. Premutation alleles in males may expand or contract by several repeats with transmission; however, expansion to full mutations has not been reported. Premutation allele prevalence in Caucasians is 1 in 1,000 males and 1 in 350 females. Full mutations are typically maternally transmitted.
The mother of a child with an FMR1 mutation is almost always a carrier of a premutation or full mutation. Women with a premutation are at risk of premature ovarian insufficiency and at small risk of FXTAS; they carry a 50% risk of transmitting an abnormal gene, which either contains a premutation copy number (55-200) or a full mutation (>200) in each pregnancy.
Men who are premutation carriers are referred to as transmitting males. All of their daughters will inherit a premutation, but their sons will not inherit the premutation. Males with a full mutation usually have mental retardation and decreased fertility.
No FDA-cleared genotyping tests were found. Thus, genotyping is offered as a laboratory-developed test. Clinical laboratories may develop and validate tests in-house (“home-brew”) and market them as a laboratory service; such tests must meet the general regulatory standards of the Clinical Laboratory Improvement Act (CLIA). The laboratory offering the service must be licensed by CLIA for high-complexity testing.
Asuragen offers the Xpansion Interpreter™ test which analyzes AGG sequences that interrupt the CGG repeats which have been suggested to stabilize alleles and protect against expansion in subsequent generations.
Related policies are –
Chromosomal Microarray (CMA) Analysis for the Genetic Evaluation of Patients with Developmental Delay/Intellectual Disability or Autism Spectrum Disorder
POLICYGenetic testing for FMR1 mutations may be considered medically necessary for the following patient populations:
POLICY GUIDELINES*According to the American College of Medical Genetics (ACMG), the following is the preferred approach to testing:
** This is due to the fact that cytogenetic testing was used prior to the identification of the FMR1 gene and is significantly less accurate than the current DNA test. DNA testing would accurately identify premutation carriers and distinguish premutation from full mutation carrier women.
The ACMG Professional Practice and Guidelines Committee made recommendations regarding diagnostic and carrier testing for fragile X syndrome to provide general guidelines to aid clinicians in making referrals for testing the repeat region of the FMR1 gene. These recommendations include testing of individuals of either sex with mental retardation, developmental delay, or autism, especially if they have any physical or behavioral characteristics of fragile X syndrome.
Physical and behavioral characteristics of fragile X syndrome include: typical facial characteristics such as an elongated face with a prominent forehead, protruding jaw, and large ears. Connective tissue anomalies include hyperextensible finger and thumb joints, hand calluses, velvet-like skin, flat feet and mitral valve prolapse. The characteristic appearance of adult males includes macroorchidism. Patients may show behavioral problems including autism spectrum disorders, sleeping problems, social anxiety, poor eye contact, mood disorders and hand-flapping or biting. Another prominent feature of the disorder is neuronal hyperexcitability, manifested by hyperactivity, increased sensitivity to sensory stimuli and a high incidence of epileptic seizures.
Investigative service is defined as the use of any treatment procedure, facility, equipment, drug, device, or supply not yet recognized by certifying boards and/or approving or licensing agencies or published peer review criteria as standard, effective medical practice for the treatment of the condition being treated and as such therefore is not considered medically necessary.
The coverage guidelines outlined in the Medical Policy Manual should not be used in lieu of the Member's specific benefit plan language.
POLICY HISTORY11/15/2012: Approved by Medical Policy Advisory Committee.
10/15/2013: Policy reviewed; no changes.
SOURCE(S)Blue Cross Blue Shield Association policy # 2.04.83
This may not be a comprehensive list of procedure codes applicable to this policy.
The code(s) listed below are ONLY medically necessary if the procedure is performed according to the "Policy" section of this document.